AbbVie Results Reflect Humira Hit In Q3
US Sales Down By Almost Two-Fifths As Adalimumab Biosimilar Competition Bites
AbbVie’s latest results offered some insights into the impact of biosimilar competition to Humira, with US sales dropping by almost two-fifths in the third quarter as several biosimilars hit the market.
